Pluri (PLUR) AI Stock Analysis

• Market Cap: $31.46M
• Dividend Yield: N/A
• Average Volume (3M): 8.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: 121.74%
• EPS Growth: 24.75%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 9,253,897
• 10 Day Avg. Volume: 13,380
• 30 Day Avg. Volume: 8,388
• PEG Ratio: 1.25
• Price to Book (P/B): -45.85
• Price to Sales (P/S): 234.79
• P/FCF Ratio: -15.82
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 32.50
• Enterprise Value/Gross Profit: 75.75
• Enterprise Value/Ebitda: -1.95
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $3.50 ▲(1.45% Upside)

Pluri's overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative equity. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable due to negative earnings. The absence of earnings call insights and corporate events leaves these areas unaddressed.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.

Strategic Partnerships

Strategic partnerships expand Pluri's market reach and provide additional funding, supporting long-term growth and innovation in its product pipeline.

Leadership Incentives

Aligning executive incentives with performance goals can drive strategic decision-making and improve operational efficiency, benefiting long-term company performance.

Negative Factors

Financial Instability

Financial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow indicates ongoing operational challenges, which may hinder Pluri's ability to sustain operations and invest in future growth without additional financing.

Profitability Challenges

Ongoing profitability challenges with negative margins suggest difficulty in achieving sustainable earnings, impacting long-term financial health and investor confidence.

Pluri Business Overview & Revenue Model

Company Description

Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.

How the Company Makes Money

Pluri generates revenue through multiple streams, primarily by commercializing its proprietary technologies and cell therapy products. The company licenses its technology to pharmaceutical and biotechnology firms, which pay upfront fees and ongoing royalties based on sales of products developed using Pluri's platform. Additionally, Pluri engages in strategic partnerships and collaborations with research institutions and healthcare organizations, which often include funding arrangements for joint research projects. The company may also generate revenue from grants and funding from government and non-profit organizations aimed at supporting innovative medical research. Overall, Pluri's revenue model is driven by the successful development and commercialization of cutting-edge therapies, along with strategic collaborations that enhance its market reach.

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges with persistent losses, negative equity, and weak cash flow. Despite revenue growth and slight improvements in cash flow, the financial health remains precarious, requiring strategic changes for stability and profitability.

Income Statement

Pluri's income statement reveals significant challenges with profitability. Despite a notable revenue growth rate of 29.21% in the latest year, the company struggles with negative net profit margins and EBIT margins, indicating ongoing losses. The gross profit margin has improved but remains insufficient to offset high operating expenses.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity and a high debt-to-equity ratio in recent years. Although the debt-to-equity ratio improved in the latest year, the negative equity and low return on equity highlight financial instability and potential solvency risks.

Cash Flow

Pluri's cash flow statement indicates some improvement in free cash flow growth, but operating cash flow remains negative. The free cash flow to net income ratio suggests that cash flow is slightly better than net income figures, yet the overall cash flow position is weak, reflecting ongoing operational challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33M	1.34M	326.00K	287.00K	234.00K	0.00
Gross Profit	569.00K	654.00K	322.00K	278.00K	-819.00K	-1.37M
EBITDA	-22.09M	-22.07M	-20.23M	-27.68M	-39.43M	-48.42M
Net Income	-22.83M	-22.58M	-20.89M	-28.32M	-41.24M	-49.87M
Balance Sheet
Total Assets	33.67M	38.68M	39.53M	50.80M	68.06M	93.54M
Cash, Cash Equivalents and Short-Term Investments	15.06M	20.61M	30.24M	40.17M	55.02M	64.95M
Total Debt	34.24M	34.05M	29.61M	29.91M	28.80M	24.58M
Total Liabilities	39.32M	39.55M	34.11M	35.50M	35.88M	36.39M
Stockholders Equity	-11.36M	-6.84M	96.00K	13.36M	30.04M	57.15M
Cash Flow
Free Cash Flow	-21.10M	-19.83M	-18.34M	-23.12M	-36.78M	-31.28M
Operating Cash Flow	-19.57M	-18.21M	-18.02M	-22.86M	-36.50M	-30.91M
Investing Cash Flow	11.29M	8.03M	10.58M	9.70M	11.78M	-7.26M
Financing Cash Flow	9.53M	9.53M	8.84M	8.02M	7.50M	61.40M

Pluri Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 3.45 is above the 20-day moving average (MA) of 3.38, below the 50-day MA of 3.72, and below the 200-day MA of 4.51, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 48.86 is Neutral, neither overbought nor oversold. The STOCH value of 40.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IGC	47 Neutral	$27.86M	-3.86	-83.34%	―	-6.51%	58.31%
MURA	43 Neutral	$36.04M	-0.24	-103.87%	―	―	24.16%
PLUR	42 Neutral	$31.46M	-1.10	―	―	121.74%	24.75%
PYPD	41 Neutral	$63.11M	-1.33	-390.53%	―	―	61.23%
ITRM	35 Underperform	$19.53M	-0.49	―	―	―	62.61%
ANTX	34 Underperform	$30.69M	-0.99	-45.91%	―	―	44.59%

Pluri Corporate Events

Pluri Grants RSUs to Executives and Board Members

On December 4, 2025, Pluri‘s board of directors granted a total of 10,248 restricted stock units (RSUs) to its Chief Executive Officer and Chief Financial Officer, and 2,885 RSUs to board members as part of its 2019 Equity Compensation Plan. This move aims to support cost-management initiatives and align leadership incentives with long-term performance goals. Additionally, Mr. Weinstein was appointed as Chairman of the Board, and Mr. Zami Aberman as Vice Chairman, with Mr. Aberman’s consultancy agreement set to terminate on January 4, 2026.

Pluri Approves Equity Awards for CEO Yaky Yanay

On October 15, 2025, Pluri Inc.’s board of directors approved a grant of equity awards to CEO Yaky Yanay for achieving certain performance objectives in fiscal year 2025. The awards include 39,050 fully vested restricted stock units and stock options for 39,050 shares, exercisable for three years at $5.00 per share. Additionally, contingent future grants of 9,266 RSUs and stock options were approved, pending the achievement of specific objectives by December 31, 2025.